Phaseline

Targets › VZVIG1

VZVIG1: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Vaccines; next expected readout Dec 2026.

Open in Phaseline: the race on VZVIG1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Beijing Luzhu Biotechnology Co., Ltd.Recombinant Herpes Zoster Vaccine (LZ901)
VZV glycoprotein E (gE) fusion protein tetramer adsorbed with aluminum hydroxide adjuvant
VZVIG1Phase 3Vaccine-Preventable DiseasesDec 2026

Conditions

Vaccine-Preventable Diseases (1)

Modalities

other (1)

Companies

Beijing Luzhu Biotechnology Co., Ltd. (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.